DAC
Data Access Commitee of mantle cell lymphoma
Dac ID | Contact Person | Access Information | |
---|---|---|---|
EGAC00001001119 | Michael Wang | miwang [at] mdanderson [dot] org | No additional information is available |
This DAC controls 1 dataset:
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001004577 | Metabolic reprogramming is linked to cancer cell growth and proliferation, metastasis, and therapeutic resistance in a multitude of cancers. Targeting dysregulated metabolic pathways to overcome resistance, an urgent clinical need in all relapsed/refractory cancers, remains difficult. Through genomics analysis of clinical specimens, we show that metabolic reprogramming towards oxidative phosphorylation (OXPHOS) and glutaminolysis is associated with therapeutic resistance to the Bruton’s tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma (MCL), an incurable B-cell lymphoma with poor clinical outcomes. Inhibition of OXPHOS with a novel, clinically applicable small molecule, IACS-010759, which targets complex I of the mitochondrial electron transport chain, results in significant growth inhibition in vitro and in vivo in ibrutinib-resistant patient-derived cancer models. This work suggests that targeting metabolic pathways to subvert therapeutic resistance is a clinically viable approach to treat highly refractory malignancies. | Illumina HiSeq 4000 | 26 |